Sally C. Pipes is the President & CEO at the Pacific Research Institute. She specializes in areas such as medicine and healthcare, pharmaceuticals, public health, and education, with a focus on healthcare administration and public policy. Her insights have been featured in numerous publications, including Florida Today, The San Diego Union-Tribune, and U.S. News & World Report.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Sally C. Pipes' coverage is heavily focused on healthcare and pharmaceuticals, with a significant emphasis on policy analysis and government impact in the United States. Her articles often cite data to support her claims, indicating that she values evidence-based insights.
Given this focus, she would likely be interested in receiving pitches from experts who can provide nuanced perspectives on healthcare policies or pharmaceutical industry trends in the U.S. Pitches offering data-driven analysis of topics such as Medicaid, Obamacare, Medicare, or medical innovation are more likely to resonate with her coverage preferences.
Additionally, considering her interest in government and politics related to healthcare policy reform in the U.S., sources with expertise in health economics or public policy would also be well suited for engaging with Sally C. Pipes' content.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Wayne Winegarden, Sally C. Pipes
The death rate from cancer in the United States has fallen by more than one-third since 1991. HIV-related mortality has dropped ninefold since 1995. Death rates for Alzheimer's, chronic respiratory diseases, and stroke have all declined in recent years, too.
By: Sally C. Pipes
Yet many large hospital systems participating in the federal 340B Drug Pricing Program are quietly doing just that—extracting billions in drug discounts with scarce oversight and no obligation to prove vulnerable patients benefit.
By: Sally C. Pipes
3-minute read Sally C. Pipes Special to the USA TODAY Network May 22, 2026, 4:01 a.m. ET
Medicare for All — a policy gaining more and more traction among progressives — could bring unanticipated human costs to New Jersey patients.
By: Sally C. Pipes
A new experimental drug for pancreatic cancer, daraxonrasib, appears to have extended the lives of some patients with advanced disease by several months, according to clinical trial results out last
Mark Cuban critiques 'big medicine' and Obamacare's role in healthcare consolidation and rising costs.
A new experimental drug for pancreatic cancer, daraxonrasib, appears to have extended the lives of some patients with advanced disease by several months, according to clinical trial results out last month.
That may not sound like much. For someone facing a terminal diagnosis, what difference does a few extra months really make, especially if the drugs that enable them cost tens of thousands of dollars, as so many cancer drugs do? That question misses the point. In medicine, the most important breakthroughs rarely arrive all at […]
By: Sally C. Pipes
Mark Cuban has a new rallying cry in his campaign to fix American healthcare: “break up big medicine.”
If single-payer ever takes hold, undoing it would be extraordinarily difficult. That is precisely why the country should reject it now.
